Get the Stockscreener App
1.04
9.47%
0.09
Pre-market:
1.05
0.01
+0.96%
Myomo Inc stock is traded at $1.04, with a volume of 1.53M.
It is up +9.47% in the last 24 hours and up +26.94% over the past month.
Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
See More
Previous Close:
$0.95
Open:
$0.9555
24h Volume:
1.53M
Relative Volume:
3.94
Market Cap:
$40.18M
Revenue:
$40.93M
Net Income/Loss:
$-15.57M
P/E Ratio:
-2.7934
EPS:
-0.3723
Net Cash Flow:
$-17.84M
1W Performance:
+14.27%
1M Performance:
+26.94%
6M Performance:
+35.81%
1Y Performance:
-67.60%
1-Day Range:
$0.9555
$1.10
1-Week Range:
$0.811
$1.10
52-Week Range:
$0.605
$3.22
Myomo Inc Stock (MYO) Company Profile
Name
Myomo Inc
Sector
Industry
Phone
617-996-9058
Address
One Broadway, 14th Floor, Cambridge, MA
Compare MYO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYO
Myomo Inc
|
1.04 | 36.71M | 40.93M | -15.57M | -17.84M | -0.3723 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Myomo Inc Stock (MYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Initiated | Craig Hallum | Buy |
| May-20-24 | Initiated | Lake Street | Buy |
| Dec-15-23 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-27-20 | Initiated | Dougherty & Company | Buy |
| Oct-02-17 | Initiated | H.C. Wainwright | Buy |
View All
Myomo Inc Stock (MYO) Latest News
MYO: Wearable robotics drive growth with expanding reimbursement and recurring revenue focus - TradingView
MYO: Recurring revenue and expanded payer coverage fuel growth and improved financial outlook - TradingView
MYO: Recurring revenue and expanded coverage drive growth, with 2026 revenue guided at $43–$46 million - TradingView
Myomo reiterates $40M–$42M 2025 revenue target as O&P channel, MyoConnect drive growth - MSN
Myomo director Kirk Thomas F buys $68,242 in company stock By Investing.com - Investing.com Nigeria
Myomo (MYO) director adds 75,006 shares through open‑market buying - Stock Titan
Myomo director Kirk Thomas F buys $68,242 in company stock - Investing.com
Myomo | 4: Statement of changes in beneficial ownership of securities-Director KIRK THOMAS F - Moomoo
Horton Capital (MYO) reports 6% Myomo stake, wins board role and pushes declassification - Stock Titan
Myomo director Manko Jr. acquires $173,907 in MYO stock - Investing.com
Myomo director Manko Jr. acquires $173,907 in MYO stock By Investing.com - Investing.com India
Director-linked Horton Capital fund boosts Myomo (NYSE: MYO) stake with open-market buys - Stock Titan
MYOMO (MYO) director Joseph M. Manko Jr. reports 2.1M-share indirect stake - Stock Titan
MYO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MYO SEC FilingsMyomo 10-K, 10-Q, 8-K Forms - Stock Titan
Myomo (MYO) CCO sells 90,231 shares, retaining 109,478-share stake - Stock Titan
H.C. Wainwright Maintains Myomo(MYO.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Myomo, Inc. (MYO) reports Q1 loss, beats revenue estimates - MSN
MYO (NYSE) Form 144: Broker lists 90,231 restricted shares for resale - Stock Titan
Myomo Appoints Joseph M. Manko to Board - Moomoo
Myomo Adds Horton Capital Executive to Board of Directors - The Globe and Mail
[ARS] MYOMO, INC. SEC Filing - Stock Titan
Myomo Announces Participation in Upcoming Investor Conferences - The Joplin Globe
Myomo (NYSE: MYO) 2026 proxy targets share increase, equity plan and declassified board vote - Stock Titan
Safeguard Scientifics stock (US78437J1007): Myomo appoints Safeguard director to board - AD HOC NEWS
Myomo appoints Joseph M. Manko to its board - Medical Buyer
Here is why bargain hunters would love fast-paced mover Myomo (MYO) - MSN
Earnings call transcript: Myomo beats Q1 2026 expectations, stock dips - Investing.com
Earnings call transcript: Myomo beats Q1 2026 expectations, stock dips By Investing.com - Investing.com Nigeria
Myomo appoints Joseph Manko to board of directors - Investing.com UK
Myomo Appoints Joseph M. Manko to its Board of Directors - 01net
Myomo appoints Joseph M. Manko to its board of directors - marketscreener.com
Myomo Appoints Joseph M. Manko To Its Board Of Directors - TradingView
Myomo appoints Joseph Manko to board of directors By Investing.com - Investing.com Australia
Joseph M. Manko joins Myomo (MYO) board, expanding it to seven directors - Stock Titan
Myomo, Inc. Appoints Joseph M. Manko Jr. as Director, Effective May 9, 2026 - marketscreener.com
Here Is Why Bargain Hunters Would Love Fast-paced Mover Myomo (MYO) - Yahoo Finance
A. G. P. Maintains Myomo(MYO.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Myomo revenue up 49% to USD 10.1M in Q1 2026 - Medical Buyer
Maxim Group Maintains Myomo(MYO.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Q1 2026 Myomo Inc Earnings Call Transcript - GuruFocus
Myomo, Inc. (MYO) Reports Q1 2026 Revenue of $10.1 Million - GuruFocus
Myomo Q1 2026 Earnings Call Transcript - MarketBeat
Myomo Reports First Quarter 2026 Financial and Operating Results - BioSpace
Myomo outlines $10.3M-$10.8M Q2 revenue while reiterating $43M-$46M for 2026 - MSN
Myomo Inc Stock (MYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):